Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Clinical communication and the 'triangle of care' in mental health and deafness: Sign language interpreters' perspectives.

Chatzidamianos G, Fletcher I, Wedlock L, Lever R.

Patient Educ Couns. 2019 May 15. pii: S0738-3991(19)30200-9. doi: 10.1016/j.pec.2019.05.016. [Epub ahead of print]

PMID:
31122818
2.

Etiology and Severity of Liver Disease in HIV-Positive Patients With Suspected NAFLD: Lessons From a Cohort With Available Liver Biopsies.

Iogna Prat L, Roccarina D, Lever R, Lombardi R, Rodger A, Hall A, Luong TV, Bhagani S, Tsochatzis EA.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):474-480. doi: 10.1097/QAI.0000000000001942.

PMID:
30807482
3.

Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies.

Iogna Prat L, Roccarina D, Lever R, Lombardi R, Rodger A, Hall A, Luong TV, Bhagani S, Tsochatzis E.

J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001942. [Epub ahead of print]

PMID:
30570530
4.

Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers.

Lombardi R, Lever R, Smith C, Marshall N, Rodger A, Bhagani S, Tsochatzis E.

Ann Gastroenterol. 2017;30(3):349-356. doi: 10.20524/aog.2017.0141. Epub 2017 Apr 3.

5.

Hexamidine salts - applications in skin health and personal care products.

Parisi N, Matts PJ, Lever R, Hadgraft J, Lane ME.

Int J Cosmet Sci. 2017 Aug;39(4):361-365. doi: 10.1111/ics.12392. Epub 2017 Mar 7. Review.

PMID:
28129440
6.

Mast cell glycosaminoglycans.

Mulloy B, Lever R, Page CP.

Glycoconj J. 2017 Jun;34(3):351-361. doi: 10.1007/s10719-016-9749-0. Epub 2016 Nov 30. Review.

7.

Biochemical and functional characterization of glycosaminoglycans released from degranulating rat peritoneal mast cells: Insights into the physiological role of endogenous heparin.

Lever R, Smailbegovic A, Riffo-Vasquez Y, Gray E, Hogwood J, Francis SM, Richardson NV, Page CP, Mulloy B.

Pulm Pharmacol Ther. 2016 Dec;41:96-102. doi: 10.1016/j.pupt.2016.11.002. Epub 2016 Nov 3.

PMID:
27816772
8.

Topical delivery of hexamidine.

Parisi N, Paz-Alvarez M, Matts PJ, Lever R, Hadgraft J, Lane ME.

Int J Pharm. 2016 Jun 15;506(1-2):332-9. doi: 10.1016/j.ijpharm.2016.04.069. Epub 2016 Apr 26.

PMID:
27130367
9.

Ebola virus disease: emergence, outbreak and future directions.

Lever RA, Whitty CJ.

Br Med Bull. 2016 Mar;117(1):95-106. doi: 10.1093/bmb/ldw005. Epub 2016 Feb 12. Review.

PMID:
26872858
10.

Pharmacology of Heparin and Related Drugs.

Mulloy B, Hogwood J, Gray E, Lever R, Page CP.

Pharmacol Rev. 2016 Jan;68(1):76-141. doi: 10.1124/pr.115.011247. Review.

PMID:
26672027
11.

Conventional protein kinase C isoforms differentially regulate ADP- and thrombin-evoked Ca²⁺ signalling in human platelets.

Lever RA, Hussain A, Sun BB, Sage SO, Harper AG.

Cell Calcium. 2015 Dec;58(6):577-88. doi: 10.1016/j.ceca.2015.09.005. Epub 2015 Sep 28.

PMID:
26434503
12.

Preparation and characterisation of hexamidine salts.

Parisi N, Matts PJ, Lever R, Hadgraft J, Lane ME.

Int J Pharm. 2015 Sep 30;493(1-2):404-11. doi: 10.1016/j.ijpharm.2015.07.071. Epub 2015 Jul 30.

PMID:
26235920
13.

Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008-2013.

Nabarro LE, Lever RA, Armstrong M, Chiodini PL.

Clin Microbiol Infect. 2015 Aug;21(8):791-6. doi: 10.1016/j.cmi.2015.04.019. Epub 2015 May 12.

14.

PEGylation and its impact on the design of new protein-based medicines.

Ginn C, Khalili H, Lever R, Brocchini S.

Future Med Chem. 2014;6(16):1829-46. doi: 10.4155/fmc.14.125. Review. Erratum in: Future Med Chem. 2014;6(18):2133.

PMID:
25407370
15.

Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium.

Lever R, Rose MJ, McKenzie EA, Page CP.

Am J Physiol Cell Physiol. 2014 Jun 15;306(12):C1184-90. doi: 10.1152/ajpcell.00269.2013. Epub 2014 Apr 16.

16.

Fab-PEG-Fab as a potential antibody mimetic.

Khalili H, Godwin A, Choi JW, Lever R, Khaw PT, Brocchini S.

Bioconjug Chem. 2013 Nov 20;24(11):1870-82. doi: 10.1021/bc400246z. Epub 2013 Nov 4.

PMID:
24073593
17.

Comparative binding of disulfide-bridged PEG-Fabs.

Khalili H, Godwin A, Choi JW, Lever R, Brocchini S.

Bioconjug Chem. 2012 Nov 21;23(11):2262-77. doi: 10.1021/bc300372r. Epub 2012 Oct 18.

PMID:
22994419
18.

Understanding the mental health needs of secondary school children in Manchester.

Hackett L, Theodosiou L, Robson C, Spicer F, Lever R.

Ment Health Fam Med. 2011 Sep;8(3):173-9.

19.

Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.

Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton PS.

Neuropeptides. 2012 Oct;46(5):183-93. doi: 10.1016/j.npep.2012.07.004. Epub 2012 Aug 22. Retraction in: Neuropeptides. 2013 Jun;47(3):221.

PMID:
22921965
20.

Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton P.

Br J Pharmacol. 2012 Dec;167(7):1467-79. doi: 10.1111/j.1476-5381.2012.02100.x. Retraction in: Br J Pharmacol. 2013 Jun;169(3):717.

21.

Non-anticoagulant effects of heparin: an overview.

Lever R, Page CP.

Handb Exp Pharmacol. 2012;(207):281-305. doi: 10.1007/978-3-642-23056-1_12. Review.

PMID:
22566229
22.

Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.

Abuirmeileh A, Harkavyi A, Rampersaud N, Lever R, Tadross JA, Bloom SR, Whitton PS.

J Pharm Pharmacol. 2012 May;64(5):637-43. doi: 10.1111/j.2042-7158.2011.01394.x. Epub 2012 Mar 27.

PMID:
22471359
23.

Intracellular defenses against HIV, viral evasion and novel therapeutic approaches.

Lever RA, Lever AM.

J Formos Med Assoc. 2011 Jun;110(6):350-62. doi: 10.1016/S0929-6646(11)60053-3. Review.

24.

Discussing stories: on how a dialogic reading intervention improves kindergartners' oral narrative construction.

Lever R, Sénéchal M.

J Exp Child Psychol. 2011 Jan;108(1):1-24. doi: 10.1016/j.jecp.2010.07.002. Epub 2010 Sep 9.

PMID:
20828708
25.

Administration of capsule-selective endosialidase E minimizes upregulation of organ gene expression induced by experimental systemic infection with Escherichia coli K1.

Zelmer A, Martin MJ, Gundogdu O, Birchenough G, Lever R, Wren BW, Luzio JP, Taylor PW.

Microbiology. 2010 Jul;156(Pt 7):2205-15. doi: 10.1099/mic.0.036145-0. Epub 2010 Apr 15.

26.

Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity.

Lever R, Smailbegovic A, Page CP.

Eur J Pharmacol. 2010 Mar 25;630(1-3):137-44. doi: 10.1016/j.ejphar.2009.12.015. Epub 2009 Dec 30.

PMID:
20043903
27.

Effects of various sodium bicarbonate loading protocols on the time-dependent extracellular buffering profile.

Siegler JC, Midgley AW, Polman RC, Lever R.

J Strength Cond Res. 2010 Sep;24(9):2551-7. doi: 10.1519/JSC.0b013e3181aeb154.

PMID:
20040895
28.

Expression of the VP2 protein of murine norovirus by a translation termination-reinitiation strategy.

Napthine S, Lever RA, Powell ML, Jackson RJ, Brown TD, Brierley I.

PLoS One. 2009 Dec 22;4(12):e8390. doi: 10.1371/journal.pone.0008390.

29.

The CRF-like peptide urocortin greatly attenuates loss of extracellular striatal dopamine in rat models of Parkinson's disease by activating CRF(1) receptors.

Abuirmeileh A, Harkavyi A, Kingsbury A, Lever R, Whitton PS.

Eur J Pharmacol. 2009 Feb 14;604(1-3):45-50. doi: 10.1016/j.ejphar.2008.11.009. Epub 2008 Nov 13.

PMID:
19026631
30.

The CRF-like peptide urocortin produces a long-lasting recovery in rats made hemiparkinsonian by 6-hydroxydopamine or lipopolysaccharide.

Abuirmeileh A, Harkavyi A, Kingsbury A, Lever R, Whitton PS.

J Neurol Sci. 2008 Aug 15;271(1-2):131-6. doi: 10.1016/j.jns.2008.04.016. Epub 2008 May 27.

PMID:
18508084
31.

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.

Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS.

J Neuroinflammation. 2008 May 21;5:19. doi: 10.1186/1742-2094-5-19.

32.
33.

The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.

Abuirmeileh A, Lever R, Kingsbury AE, Lees AJ, Locke IC, Knight RA, Chowdrey HS, Biggs CS, Whitton PS.

Eur J Neurosci. 2007 Jul;26(2):417-23.

PMID:
17650114
34.

Size-fractionated heparins have differential effects on human neutrophil function in vitro.

Lever R, Lo WT, Faraidoun M, Amin V, Brown RA, Gallagher J, Page CP.

Br J Pharmacol. 2007 Jul;151(6):837-43. Epub 2007 May 29.

35.

Effect of tecastemizole on pulmonary and cutaneous allergic inflammatory responses.

Lever R, Hefni A, Moffatt JD, Paul W, Page CP.

Clin Exp Allergy. 2007 Jun;37(6):909-17.

PMID:
17517105
36.

Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice.

Moffatt JD, Lever R, Page CP.

FASEB J. 2006 Sep;20(11):1877-9. Epub 2006 Jul 19.

PMID:
16855006
37.

Narrowband ultraviolet B (UVB) phototherapy in children.

Jury CS, McHenry P, Burden AD, Lever R, Bilsland D.

Clin Exp Dermatol. 2006 Mar;31(2):196-9.

PMID:
16487089
38.

The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.

Jones NA, Boswell-Smith V, Lever R, Page CP.

Pulm Pharmacol Ther. 2005;18(2):93-101. Epub 2004 Dec 8.

PMID:
15649851
39.

Anti-adhesive glycoproteins in echinoderm mucus secretions.

Bavington CD, Lever R, Mulloy B, Grundy MM, Page CP, Richardson NV, McKenzie JD.

Comp Biochem Physiol B Biochem Mol Biol. 2004 Dec;139(4):607-17.

PMID:
15581793
40.

Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system.

Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P, Carbonatto M, Mack M, Smailbegovic A, Rose M, Lever R, Page C, Wells TN, Proudfoot AE.

J Immunol. 2004 Nov 1;173(9):5776-85.

41.

Effects of inhaled thrombin receptor agonists in mice.

Moffatt JD, Lever R, Page CP.

Br J Pharmacol. 2004 Sep;143(2):269-75. Epub 2004 Aug 9.

42.

Platelets are essential for leukocyte recruitment in allergic inflammation.

Pitchford SC, Yano H, Lever R, Riffo-Vasquez Y, Ciferri S, Rose MJ, Giannini S, Momi S, Spina D, O'connor B, Gresele P, Page CP.

J Allergy Clin Immunol. 2003 Jul;112(1):109-18.

PMID:
12847487
43.

Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro.

Brown RA, Lever R, Jones NA, Page CP.

Br J Pharmacol. 2003 Jun;139(4):845-53.

44.

Novel drug development opportunities for heparin.

Lever R, Page CP.

Nat Rev Drug Discov. 2002 Feb;1(2):140-8. doi: 10.1038/nrd724. Review.

PMID:
12120095
46.

Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness.

Lever R, Page C.

Pulm Pharmacol Ther. 2001;14(3):249-54. Review.

PMID:
11448151
47.

The role of food in atopic eczema.

Lever R.

J Am Acad Dermatol. 2001 Jul;45(1 Suppl):S57-60. No abstract available.

PMID:
11423877
48.

iNOS in arthritis--inducible or innocent?

Lever R.

Trends Pharmacol Sci. 2001 May;22(5):220-1. No abstract available.

PMID:
11339961
49.

A new enzyme: insights into mechanisms of cell trafficking.

Lever R.

Trends Pharmacol Sci. 2000 Dec 1;21(12):460. No abstract available.

PMID:
11121833
50.

HIT dynamics are Fab.

Lever R.

Trends Pharmacol Sci. 2000 Sep;21(9):330. No abstract available.

PMID:
10973080

Supplemental Content

Support Center